Evidence map›Paper›PMID 40007549›Full record

ArticleJTO clinical and research reports2025

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50.

Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, Yasushi Fukuda, Akihiro Bessho, Tadaaki Yamada, Yukihiro Toi, Tomoki Kimura, Hiroshige Yoshioka, Koichi Azuma and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04396457 (Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04396457 phase2unknown statusnot on this map

Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901

TypeinterventionalSponsorNational Hospital Organization Nagoya Medical CenterRan2020 to 2024Enrolled50ConditionsNon-squamous Non-small-cell Lung Cancer, Cancer, LungArmsPembrolizumab, Pemetrexed
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yoshihito KogureDepartment of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan.
Hiroya HashimotoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Haruko DagaDepartment of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Yasushi FukudaDepartment of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
Akihiro BesshoDepartment of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Tadaaki YamadaDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yukihiro ToiDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Tomoki KimuraDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Hiroshige YoshiokaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
Koichi AzumaDepartment of Internal Medicine, Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Kurume-Shi, Japan.
Naoki FuruyaDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Yasutaka FukuiDepartment of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Japan.
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Nobuyuki YamamotoDepartment of Pulmonary Medicine and Medical Oncology, Wakayama Medical University, Wakayama, Japan.
Hideo SakaDepartment of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan.
Masashi KondoDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pembrolizumab with pemetrexed and cisplatin/carboplatin is an approved first-line treatment for metastatic nonsquamous NSCLC. Nevertheless, its efficacy and safety in patients aged 75 years and above remain unclear. We assessed the efficacy and safety of pembrolizumab with pemetrexed in patients with programmed cell death-ligand 1 expression tumor proportion scores of less than 50%. Methods: This multicenter, open-label, phase 2 trial involved 42 institutions across Japan. Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing Results: Forty-nine patients were enrolled in this study between July 2020 and May 2022. The objective response rate was 36.7% (95% confidence interval [CI]: 23.4%-51.7%). The disease control rate was 65.3% (95% CI: 50.4-78.3%). The median progression-free survival was 7.6 months (95% CI: 4.8-16.2), and the median overall survival was 19.4 months (95% CI: 11.8 mo-unreached). The most common grade 3 or 4 adverse events were neutropenia (31.3%), leukopenia (20.8%), and anemia (12.5%). No treatment-related deaths occurred during this period. Conclusions: Pembrolizumab with pemetrexed is a promising first-line treatment option for older patients with metastatic nonsquamous NSCLC. This trial was registered at ClinicalTrials.gov (NCT04396457) and the Japan Registry of Clinical Trials (jRCTs041200012).

Indexed as

Nonsquamous non-small cell lung cancerOlder patientsPembrolizumabPemetrexedProgrammed cell death 1

Identifiers

PMID40007549
PMCPMC11850748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.